
At an AJMC roundtable, Boston clinicians detailed fragmented obesity care access, prior authorization burdens, and looming GLP-1 coverage shifts.

At an AJMC roundtable, Boston clinicians detailed fragmented obesity care access, prior authorization burdens, and looming GLP-1 coverage shifts.

Clinicians say workflow changes, not education alone, are closing screening and treatment gaps in cardio-kidney-metabolic (CKM) care.

A Boston population health roundtable examined why patients with atopic dermatitis often stayed undertreated despite an expanding set of therapeutics.

Participants highlight critical gaps in the diagnosis, treatment, and coordination of care for patients with heart failure.

A multidisciplinary Philadelphia roundtable surfaced the structural barriers that keep people with AD from reaching effective therapy.

Boston specialists discussed CKM syndrome, UACR screening gaps, and GDMT sequencing at a population health roundtable.

Clinicians and pharmacists at Temple and Penn discuss barriers to multidisciplinary obesity care, from ICD-10 coding gaps to prior authorization burdens.

Participants exposed critical gaps in the diagnosis, treatment, and coordination of care for patients with heart failure with preserved ejection fraction and charted a path forward.

Clinicians discussed the fragmented state of obesity care, emphasizing the need for coordinated models, earlier intervention, and improved access to effective therapies.

A multidisciplinary roundtable exposed deep inequities in vitiligo care—from payer misclassification to access barriers—while charting a more ambitious treatment future.

Experts at a roundtable in Boston, Massachusetts, on November 19, 2025, discussed multidisciplinary strategies for obesity care, including systemic and operational barriers and scalable solutions to promote patient ownership.

Experts at a roundtable in Boston, Massachusetts, on November 3, 2025, discussed improving early Alzheimer disease diagnosis, addressing workforce and equity gaps, and expanding access to new disease-modifying therapies.